BioCentury
ARTICLE | Regulation

GSK maintains lead in BCMA race with FDA panel’s recommendation

July 14, 2020 11:53 PM UTC

If FDA follows a Tuesday recommendation by ODAC, GSK’s belantamab mafodotin would be the first BCMA-targeted therapy to gain approval.

The unanimous vote by FDA’s Oncologic Drugs Advisory Committee in favor of the BCMA-targeting antibody-drug conjugate despite a risk of vision loss highlights the potential benefits of the first-in-class therapy for multiple myeloma patients...